{
    "clinical_study": {
        "@rank": "9939", 
        "arm_group": {
            "arm_group_label": "Nimotuzumab+chemoradiotherapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the feasibility and efficacy of preoperative\n      nimotuzumab injection combined with concurrent chemoradiotherapy for initially inoperable,\n      locally advanced cervical cancer."
        }, 
        "brief_title": "Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Locally Advanced Cervical Cancer", 
        "condition_browse": {
            "mesh_term": "Uterine Cervical Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically proven squamous cell cervical cancer\n\n          -  Stages IB2-IIIB according to FIGO Staging System\n\n          -  Age:18-75\n\n          -  ECOG\uff1c2\n\n          -  Normal bone marrow function\n\n          -  Initial assessed and considered not candidates for operation\n\n          -  Signed study-specific consent form\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  Patients with other malignancies\n\n          -  Patients who received radiotherapy or chemotherapy previously\n\n          -  Presence of uncontrolled life-threatening illness\n\n          -  Allergy to platinum or monoclonal antibody"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938105", 
            "org_study_id": "WJPMF-2013-428-2081"
        }, 
        "intervention": {
            "arm_group_label": "Nimotuzumab+chemoradiotherapy", 
            "description": "Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.\n--------------------------------------------------------------------------------", 
            "intervention_name": "Nimotuzumab+chemoradiotherapy", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Cervical cancer", 
            "Nimotuzumab", 
            "Intensity-modulated radiation therapy", 
            "Concurrent chemoradiotherapy"
        ], 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "contact": {
                "email": "gxheminglu@sina.com", 
                "last_name": "Heming Lu, MS", 
                "phone": "+86-771-218-6503"
            }, 
            "facility": {
                "address": {
                    "city": "Nanning", 
                    "country": "China", 
                    "state": "Guangxi", 
                    "zip": "530021"
                }, 
                "name": "People's Hospital of Guangxi Zhuang Autonomous Region"
            }, 
            "investigator": [
                {
                    "last_name": "Heming Lu, MS", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yun Mo, MS", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Preoperative Concurrent Chemoradiotherapy Combined With Nimotuzumab Injection for Locally Advanced Cervical Cancer: a Phase II Study", 
        "overall_contact": {
            "email": "gxheminglu@sina.com", 
            "last_name": "Heming Lu, MS", 
            "phone": "+86-771-218-6503"
        }, 
        "overall_official": [
            {
                "affiliation": "People's Hospital of Guangxi", 
                "last_name": "Heming Lu, MS", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "People's Hospital of Guangxi", 
                "last_name": "Heming Lu, MS", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "People's Hospital of Guangxi", 
                "last_name": "Yun Mo, MS", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Acute and chronic toxicities.", 
                "measure": "Treatment related toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "at 1 year"
            }, 
            {
                "measure": "Tumor response after preoperative treatment", 
                "safety_issue": "No", 
                "time_frame": "assessed at 4-5 weeks after the completion of preoperative treatment"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938105"
        }, 
        "responsible_party": {
            "investigator_affiliation": "People's Hospital of Guangxi", 
            "investigator_full_name": "Heming Lu", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "at 1 year"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "at 1 year"
            }
        ], 
        "source": "People's Hospital of Guangxi", 
        "sponsors": {
            "collaborator": {
                "agency": "Wu Jieping Medical Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "People's Hospital of Guangxi", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}